New findings by the researchers can keep acute pancreatitis, a common disease of the pancreas at bay.

On Wednesday, April 13, an international research team determined to figure out and eventually manipulate the activation of such enzymes will present an important new finding at the Experimental Biology 2011 meeting in Washington, D.C.
"Acute pancreatitis is the most frequent disease of the pancreas, diabetes is the most prevalent chronic disease of the pancreas and pancreatic cancer is one of the most devastating cancers. Our finding could in the future arm us to better battle or to prevent these serious diseases," explains Mar'a I. Vaccaro, who oversaw the team's work and who will give a talk about their finding at 10:25 a.m. in Room 207A of the Walter E. Washington Convention Center.
Writing in a Journal of Biological Chemistry "Paper of the Week" last month, Vaccaro's team identified for the first time a cellular process that the pancreas uses to selectively detect and degrade activated enzymes before they can digest the organ, avoiding the progression of disease.
The research team, which included participants from the University of Buenos Aires, the National Institute of Health and Medical Research in France and the Mayo Clinic in Rochester, Minn., has dubbed the cellular process "zymophagy."
"Our results showed that there is a refined mechanism that the pancreas switches on to avoid the progression of the disease to a lethal condition. The paradoxical and amazing fact is that this protective process is a form of autophagy," Vaccaro says.
Advertisement
The team coined the new form of autophagy "zymophagy" because the dangerous components that get gobbled up are called zymogen granules.
Advertisement
Acute pancreatitis is a painful disease that ranges from a mild and autolimited process to a severe and eventually lethal condition. Vaccaro says this protective cell-defense strategy could explain, at least in part, the autolimited form of the disease that seen in many patients.
"Hence, the more efficient zymophagic response by the pancreatic acinar cell, the less severity of the disease," she says. "Our study also identified the molecules that mediate the zymophagy. Therefore, it would be possible that in the future, a kind of test to evaluate zymophagy capacity in patients could help to predict the progression of the disease and modify the therapeutic approaches."
Source-Eurekalert